HCT-8 (HRT-18) Xenograft Model Service for Colon Cancer

The HCT-8 (HRT-18) xenograft model offers a robust and clinically relevant platform for evaluating therapeutic efficacy against ileocecal colorectal adenocarcinoma in vivo. At Alfa Cytology, we specialize in delivering validated, high-quality HCT-8 (HRT-18) xenograft model services tailored to support your preclinical colon cancer research programs---from compound screening and pharmacokinetic assessment to biomarker-driven efficacy studies---ensuring reliable, reproducible data to advance your drug development pipeline.

Overview of HCT-8 (HRT-18) Xenograft Model for Colon Cancer

The HCT-8 cell line, also designated HRT-18, was originally established from the ileocecal region of a 67-year-old Caucasian male patient diagnosed with colorectal adenocarcinoma. This continuous epithelial cell line exhibits polygonal morphology, grows in adherent monolayers, and possesses the distinctive capability to grow in both adherent and semi-suspended culture states---a feature characteristic of transitional metastatic stages. Genotypically, HCT-8 cells are hypertriploid and harbor several chromosomal aberrations common in colorectal carcinomas, including a well-documented mutation in codon 13 of the KRAS gene (Gly to Asp substitution). The line demonstrates high proliferative capacity, expresses carcinoembryonic antigen (CEA) at approximately 0.5 ng per 10^6 cells per 10 days, and produces alkaline phosphatase and keratin, making it a well-characterized system for studying colon cancer biology, chemoresistance mechanisms, and metastatic behavior.

In immunocompromised murine hosts, HCT-8 (HRT-18) cells exhibit consistent tumorigenicity, forming palpable tumors within approximately 21 days at 100% frequency when inoculated subcutaneously at 10^7 cells per mouse. This predictable growth kinetics and high take rate render the HCT-8 xenograft model particularly valuable for preclinical pharmacology studies, including the evaluation of novel chemotherapeutic agents, targeted biologics, and combination regimens. The model has been widely employed to investigate molecular pathways governing cancer cell proliferation, apoptosis, and drug resistance, as well as to assess anti-tumor immune responses and tumor microenvironment dynamics in colon adenocarcinoma.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting ileocecal colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through KRAS codon 13 mutation, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. Anti-colorectal carcinoma properties of Equisetum arvense L against HT-29 (A), HCT 116 (B), HCT-8 [HRT-18] (C), and Ramos.2G6.4C10 (D) cell lines. (Wang, Lei, et al., 2021)

Cell Line Information: HCT-8 (HRT-18)

The HCT-8 (HRT-18) cell line is a well-established human ileocecal colorectal adenocarcinoma line with comprehensive molecular characterization. Its ability to grow in both adherent and semi-suspended states, KRAS codon 13 mutation, and high tumorigenicity make it unique among available colon cancer cell lines and essential for preclinical research targeting transitional metastatic stages of colorectal carcinoma.

Our Services

Alfa Cytology provides comprehensive, end-to-end HCT-8 (HRT-18) xenograft model services designed to accelerate your colon cancer drug discovery pipeline. Our integrated platform encompasses model establishment, in-life study management, tumor monitoring via caliper or advanced imaging modalities, endpoint analysis including histopathology and biomarker profiling, and detailed data reporting---ensuring rigorous scientific standards and full regulatory compliance for your preclinical research needs.

Workflow of HCT-8 (HRT-18) Xenograft Model Construction

Construction of the HCT-8 (HRT-18) xenograft model follows a standardized, quality-controlled workflow optimized for high tumor take rates and reproducible growth kinetics. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Expansion and Authentication: HCT-8 (HRT-18) cells are revived from authenticated master stocks, expanded under adherent culture conditions in RPMI-1640 supplemented with 10% serum, and verified for identity via STR profiling and mycoplasma testing prior to inoculation.
2. Pre-Inoculation Cell Preparation: Exponentially growing cells are harvested using trypsin-EDTA digestion, washed with sterile PBS, and resuspended at a predetermined concentration (typically 1x10^7 cells per 100--200 uL) in serum-free medium or Matrigel mixture on the day of implantation.
3. Animal Preparation and Subcutaneous Inoculation: Immunocompromised mice (e.g., nude or NOD-SCID) are acclimatized and randomized into study groups. The HCT-8 cell suspension is injected subcutaneously into the flank region using aseptic technique to establish palpable tumors.
4. Tumor Monitoring and Randomization: Tumor growth is monitored by blinded caliper measurement two to three times weekly. Upon reaching a mean tumor volume of approximately 100--150 mm^3, animals are randomized into treatment cohorts to minimize inter-group variability.
5. Dosing and In-Life Assessment: Test articles are administered according to the study design (e.g., intraperitoneal, intravenous, or oral gavage). Body weight, clinical signs, and tumor dimensions are recorded systematically throughout the dosing period to assess anti-tumor efficacy and tolerability.
6. Endpoint Analysis and Tissue Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses including H&E histopathology, immunohistochemistry (IHC), biomarker expression profiling, and pharmacokinetic/pharmacodynamic correlation.

Figure 2: Schematic workflow illustrating the derivation and construction of the HCT-8 (HRT-18) Xenograft Model at Alfa Cytology.

Case Study-HCT-8 (HRT-18) Xenograft Model Development

Alfa Cytology has successfully developed and validated the HCT-8 (HRT-18) subcutaneous xenograft model for colon cancer preclinical studies. In a representative engagement, immunocompromised mice were inoculated with authenticated HCT-8 cells, achieving consistent tumor engraftment within the expected latency period. Tumor-bearing animals were subsequently enrolled into a treatment study evaluating candidate therapeutic agents, with longitudinal tumor growth monitoring demonstrating dose-dependent anti-tumor responses. Comprehensive endpoint analyses---including tumor growth inhibition metrics, body weight tracking, and histopathological evaluation---were performed to support client decision-making. Detailed study parameters, raw data, and statistical analyses are available upon request under appropriate confidentiality agreements.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HCT-8 (HRT-18) xenograft model program ensures access to a scientifically rigorous, quality-driven preclinical service platform. Our differentiated capabilities include:

• Verified Cell Line Integrity: Authenticated Cell Lines: All studies utilize STR-verified, mycoplasma-free HCT-8 (HRT-18) master stocks with documented passage control to preserve genetic stability and tumorigenic consistency.
• High Take Rates and Consistency: High Tumor Take Rates: Our optimized inoculation protocols consistently achieve 100% engraftment frequency with predictable tumor growth kinetics, minimizing study variability and animal usage.
• Comprehensive Analytical Support: Customizable Study Designs: Flexible dosing schedules, route-of-administration options, and combination therapy arms are tailored to match your specific compound profile and development stage.
• Tailored Study Designs: Integrated Endpoint Analysis: Comprehensive histopathology, IHC, biomarker quantification, and PK/PD correlation services are available within a single project workflow.
• Standardized Protocols: Regulatory Compliance: All procedures are conducted under IACUC-approved protocols with stringent adherence to animal welfare guidelines and GLP-compatible documentation standards.
• Dedicated Project Management: Rapid Project Turnaround: Dedicated project management and streamlined workflows enable accelerated study initiation and timely delivery of interim and final reports.

Contact Us

Ready to advance your colon cancer preclinical program with a validated HCT-8 (HRT-18) xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, or schedule a consultation with our scientific team. Please reach out to us today via our inquiry form or email to learn more about our HCT-8 (HRT-18) Xenograft Model services.

For research use only. Not intended for any clinical use.